Tecentriq 1200mg Injection

Product Description

1. Technical Specifications

---

2. Product Description

Tecentriq contains atezolizumab, a humanized monoclonal antibody that binds programmed death-ligand 1 (PD-L1) on tumour cells and tumour-infiltrating immune cells. By blocking PD-L1 interaction with PD-1 and B7.1, it restores anti-tumour T-cell activity and enhances immune-mediated tumour cell killing. It is used alone or in combination with other agents for selected advanced cancers.

---

3. Product Highlights

---

4. Therapeutic Uses

• Non-Small Cell Lung Cancer (NSCLC): as monotherapy or in combination regimens for specific settings (dependent on histology, PD-L1 status and line of therapy).

• Extensive-Stage Small Cell Lung Cancer (ES-SCLC): in combination with platinum-etoposide for first-line treatment (where approved).

• Urothelial Carcinoma: for locally advanced or metastatic disease in selected settings (including maintenance use).

• Hepatocellular Carcinoma (HCC): in combination with bevacizumab for selected patients.

• Triple-Negative Breast Cancer (TNBC): in combination with chemotherapy for PD-L1positive advanced disease.

• Other indications per local approval and label. Always confirm indication and patient selection (biomarkers, prior therapy) before use.

---

5. Side Effects

Common:

• Fatigue, nausea, decreased appetite

• Rash, pruritus

• Diarrhea

• Infusion-related reactions (fever, chills, hypotension, dyspnea)

Immune-mediated (important / potentially severe):

• Pneumonitis (new/worsening cough, dyspnea)

• Colitis (diarrhea, abdominal pain)

• Hepatitis (elevated AST/ALT, bilirubin)

• Endocrinopathies (hypothyroidism, hyperthyroidism, hypophysitis adrenal insufficiency)

• Nephritis (renal dysfunction)

• Dermatologic reactions (severe skin reactions are rare)

Serious / Rare:

• Severe or life-threatening immune-related adverse events across organ systems

• Severe infections in immune-suppressed patients

---

6. Precautions & Monitoring

• Baseline tests: CBC, liver function tests (AST/ALT, bilirubin), renal function, thyroid function (TSH free T4), and other tests as indicated. Screen for active infections per institutional practice.

• Monitoring during therapy: Periodic LFTs, renal function, thyroid tests, and clinical assessment for signs/symptoms of immune-mediated toxicity. Monitor for infusion reactions during and after infusion.

• Management of immune-related AEs: Early recognition and prompt immunosuppressive therapy (corticosteroids) for moderate-to-severe events; hold or permanently discontinue therapy for severe or life-threatening toxicities per protocol.

• Vaccinations: Avoid live vaccines during treatment and until immune recovery.

• Pregnancy & Lactation: Use in pregnancy only if clearly needed; advise effective contraception during treatment and for a period after last dose. Avoid breastfeeding during therapy.

• Concomitant medications: Exercise caution with immunosuppressants; review agents that may mask immune-related AEs (e.g., systemic steroids) before starting therapy.

---

7. Administration & Practical Points

• Reconstitute/dilute and administer according to product label and institutional pharmacy procedures.

• Premedication is not routinely required for most patients but may be used if prior infusion reactions occurred; follow institution guidance.

• Infusion rate: initial infusion 60 minutes; if tolerated, subsequent infusions may be given over 30 minutes. Do not administer as IV push/bolus.

• Use aseptic technique and in-line filter if recommended by manufacturer. Dispose of unused product and materials as per local regulations.

---

8. Handling & Storage

• Store refrigerated (28 C); do not freeze or shake. Protect from light.

• Prepare in a certified biological safety cabinet when required; observe cytotoxic/biologic handling precautions as per institutional policy.

• Discard unused portion vials are single-use.

Advanced Immunotherapy for Cancer Care

Tecentriq 1200mg Injection represents a significant development in cancer treatment options. Its formulation targets specific pathways to help the bodys immune system fight certain cancers more effectively. As a prescription-only medication, it is intended for use under strict medical supervision, ensuring both safety and optimal benefit for adult patients.


Reliable Supply and Distribution

Our distribution network provides Tecentriq 1200mg Injection to healthcare providers, exporters, suppliers, and wholesalers across India. Each batch is sourced with an emphasis on quality and reliability, ensuring that you receive authentic medicine handled under optimal storage conditions for maximum efficacy.